News

Pegaspargase-Modified Risk-Oriented Regimen for Patients With Philadelphia Chromosome–Negative ALL

10/24/2023

The addition of a pegaspargase-modified risk-oriented program to treatment regimens improved outcomes for patients with Philadelphia chromosome–negative acute lymphoblastic leukemia/lymphoma, according to the GIMEMA LAL1913 trial.

The addition of a...

10/24/2023

Oncology

News

Third-Generation CD19-Directed CAR-T Cell Treatment Shows Promising Efficacy for Patients With R/R ALL

09/25/2023

Amber Denham ;

Third-generation CAR-T cells for the treatment of patients with relapsed/refractory ALL were associated with promising clinical efficacy and low procedure-specific toxicity, according to the first report of a phase 1/2 trial.

Third-generation CAR-T cells for...

09/25/2023

Oncology

News

Mini-Hyper CVD Chemotherapy Plus Inotuzumab Ozogamicin Regimen With or Without Blinatumomab Demonstrates Efficacy, Safety for R/R Pre-B ALL

07/06/2023

Jordan Kadish ;

Mini-hyper-CVD plus inotuzumab with or without blinatumomab showed efficacy in patients with relapsed/refractory pre-B ALL, with improved survival after the addition of blinatumomab, according to an updated analysis of a phase 2 trial.

Mini-hyper-CVD plus inotuzumab...

07/06/2023

Oncology

News

Donor-Derived CD7 CAR T-Cell Therapy Demonstrated Durable Efficacy Among Subset of Patients With R/R T-Cell ALL

06/22/2023

Jordan Kadish ;

2-year follow-up results from a phase 1 study indicated that donor-derived CD7 CAR T-cell therapy demonstrated durable efficacy among a subset of patients with R/R T-cell acute lymphoblastic leukemia.

2-year follow-up results from a...

06/22/2023

Oncology

News

Dose-Adjusted EPOCH Regimen Yielded Deep and Durable Remissions Among Patients With ALL

05/18/2023

Jordan Kadish ;

According to findings from a phase 2 trial, a dose-adjusted EPOCH regimen yielded deep and durable remissions among patients with ALL and was comparable to some resource-intensive strategies of treatment.

According to findings from a...

05/18/2023

Oncology

News

Intramuscular JZP458 for Patients With AML With Hypersensitivity to E. Coli-Derived Asparaginases

04/14/2023

Jordan Kadish ;

According to findings of a phase 2/3 trial, intramuscular JZP458 yielded safe and effective results among patients with ALL or lymphoblastic leukemia with hypersensitivity/silent inactivation to asparaginases.

According to findings of a phase...

04/14/2023

Oncology

News

Inotuzumab Ozogamicin Induction Yielded High Remission Rates in Older Adults With De Novo Acute B-Lymphoblastic Leukemia

02/08/2023

Jordan Kadish ;

Inotuzumab ozogamicin induction therapy for adults with de novo acute B-lymphoblastic leukemia resulted in high remission rates, according to a phase 2 study.

Inotuzumab ozogamicin induction...

02/08/2023

Oncology

News

Blinatumomab During Consolidation May Benefit Patients With High-Risk Ph-Negative BCP Acute Lymphoblastic Leukemia

02/08/2023

Jordan Kadish ;

Results from the GRAALL-2014/B 2-cohort comparison study presented at the 2022 ASH Annual Meeting & Exposition found blinatumomab during consolidation demonstrated a significant reduction of the risk of relapse among patients with high-risk...

Results from the GRAALL-2014/B...

02/08/2023

Oncology

News

Chemotherapy Plus Ponatinib Followed by Transplant Well-Tolerated in Adults With Philadelphia–Positive ALL

10/18/2022

Gina Tomaine ;

The combination of chemotherapy with ponatinib followed by alloHSCT is well-tolerated in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia, according to a phase 2 trial.

The combination of chemotherapy...

10/18/2022

Oncology

News

Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide for ALL

09/20/2022

Gina Tomaine ;

Busulfan plus cyclophosphamide demonstrated noninferior efficiency and safety compared with total body irradiation plus cyclophosphamide for adult patients with standard-risk B-cell ALL in a phase 3 trial.

Busulfan plus cyclophosphamide...

09/20/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology